Opinion|Videos|September 3, 2024
Optimizing BPH Management: Evaluating MIST Options and Key Treatment Considerations
Fact checked by: Dean Elterman, MD, MSc
Dean Elterman, MD, compares minimally invasive surgical therapy (MIST) options for prostate treatment, discussing factors influencing choice, patient experience differences, and clinical and nonclinical factors such as prostate size, symptom severity, and patient preferences.
Advertisement
Video content above is prompted by the following:
- What are some of the key differences in the minimally invasive surgical therapy (MIST) options (prostatic urethral lift [PUL], water vapor thermal therapy, robotic waterjet treatment, photoselective vaporization of the prostate)?
- Please explain factors that may lead you to choose one MIST option over another.
- In terms of patient experience, what are some key differences in MIST options?
- Please speak of factors such as the need for local/general anesthesia, recovery time, time to symptom relief, preservation of sexual function, durability, etc.
- What clinical and nonclinical factors impact your treatment choice?
- Please speak to factors such as patient prostate size and symptom severity, common comorbidities, efficacy and durability, recovery time, and possible risks or adverse events.
- Does a PUL give you more confidence for treating a wide range of patients if the indication for prostate volume is larger (≤100 cc) compared with other options (30-80 cc)?
- What role does patient preference play in choosing the right treatment?
Advertisement
Related to this article
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.
Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.
BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.
Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Patient priorities and practice logistics should guide therapy selection in BCG-unresponsive NMIBC, according to Katie S. Murray, DO, MS, FACS.
Advertisement
Advertisement
Trending on Urology Times
1
Patient priorities guide treatment choice in BCG-unresponsive NMIBC
2
Modern BCG outperforms historic benchmarks in high-risk NMIBC
3
Q&A: Gary Kirsh, MD, on health policy for independent urology
4
Suzanne B. Merrill, MD, on the evolving perioperative landscape in MIBC
5